CCM
BMY.RT

Chiron Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Chiron Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-107,333
Closed -$74K – 88
2020
Q4 		$74K Sell
107,333
-72,701
-40% -$155K 0.06% 77
2020
Q3 		$405K Buy
+180,034
New +$514K 0.33% 43

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Chiron Capital Management's BMY.RT Position: Q1 2021 in Review

Chiron Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 107,333 shares — an estimated $74K sold.

Chiron Capital Management first reported a position in BMY.RT in Q3 2020 and held it in 2 quarters. The position peaked at $405K in Q3 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Chiron Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Chiron Capital Management sold 107,333 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $74K.
  • Chiron Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q3 2020 and held it in 2 quarters.
  • Chiron Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $405K in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Chiron Capital Management's 13F filing for Q1 2021, filed 18 May 2021.